Blockchain Registration Transaction Record

Soligenix Reports Breakthrough in Treating Rare Cancer CTCL

Benzinga reports on Soligenix Inc.'s potential breakthrough in treating the rare cancer, CTCL, with its lead product candidate, HyBryte. The news highlights the efficacy and safety of HyBryte in clinical studies, signaling hope for individuals living with mycosis fungoides.

<p>This news matters as it highlights the potential breakthrough in treating a rare and incurable cancer, CTCL. Soligenix's progress with HyBryte offers hope to individuals living with mycosis fungoides, a chronic and challenging disease. The company's commitment to developing innovative treatment options for rare diseases demonstrates a meaningful impact on the lives of patients worldwide.</p>